The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index; none of the 30 sources its claims cite is checked for support yet.
Persistent β 2 *-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder
Open accessAbstract
BACKGROUND: Modulation of nicotinic acetylcholine receptors (nAChRs), specifically those containing the β2 subunit, may be effective in treating patients with major depressive disorder. Using [123I]5-I-A-85380 single photon emission computed tomography (SPECT), the authors studied the availability of β2-subunit-containing nAChRs (β2*-nAChRs) in depressed patients. To understand its molecular basis, the authors also studied β2*-nAChR binding in postmortem brain samples from depressed subjects. METHOD: The participants were 23 medication-free, nonsmoking subjects with familial, early-onset depression (eight acutely ill and 15 recovered) and 23 age- and gender-matched nonsmoking comparison subjects. Each received one [123I]5-I-A-85380 SPECT scan and an MRI scan. The availability of β2*-nAChRs was quantified as VT/fP. Postmortem analysis of β2*-nAChR binding was conducted with [123I]5-I-A-85380 on prefrontal cortex samples from 14 depressed subjects and 14 age-matched comparison subjects. RESULTS: The β2*-nAChR availability in both the acutely ill and recovered depressed subjects was significantly lower across all brain regions than in the respective comparison subjects, and it was lower in the acutely ill subjects than in those who were recovered. In the depressed patients, β2*-nAChR availability was significantly correlated with lifetime number of depressive episodes, trauma score, and anxiety score. There were no differences in β2*-nAChR number between groups in the postmortem study. CONCLUSIONS: Depressed patients have lower β2*-nAChR availability than do healthy subjects. The difference between β2*-nAChR availability in vivo and in post-mortem samples may be analogous to data with dopaminergic PET ligands and dopamine receptor availability; lower receptor availability for the SPECT ligand could be caused by greater endogenous acetylcholine.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In medication-free, non-smoking patients with familial major depressive disorder (MDD), β2*-nicotinic acetylcholine receptor (β2*-nAChR) availability measured by [123I]5-I-A-85380 SPECT was lower in acutely depressed and recovered subjects than in controls, and lower in acutely depressed than recovered subjects. Postmortem prefrontal cortex showed no difference in β2*-nAChR number, suggesting lower in vivo availability may reflect increased endogenous acetylcholine rather than receptor loss.
Key findings
- Acutely depressed MDD subjects had decreased β2*-nAChR availability versus controls in 9 of 11 regions examined, except hippocampus and amygdala (all adjusted p<0.007); the omnibus model showed a significant group effect (F(3,42)=8.65, p<.0001) and group-by-region interaction (F(30,420)=1.82, p=.006).
- Recovered MDD subjects had lower β2*-nAChR availability than controls in frontal cortex (adjusted p=0.03), anterior cingulate (adjusted p=0.04), and thalamus (adjusted p=0.008); overall group effect F(1,28)=7.9, p=0.009.
- Acutely depressed subjects had lower overall β2*-nAChR availability than recovered subjects (F(1,21)=10.0, p=0.005), with no significant group-by-region interaction (F(10,210)=1.34, p=0.21).
- Postmortem prefrontal cortex showed no differences in β2*-nAChR number between 14 MDD subjects and age-matched controls; in vivo availability correlated positively with lifetime number of depressive episodes in combined MDD subjects for temporal cortex (r=0.46, p=0.049), occipital cortex (r=0.48, p=0.037), and striatum (r=0.49, p=0.034).
Methods
- Cross-sectional SPECT/MRI study: 23 medication-free, non-smoking subjects with recurrent familial MDD (8 acutely depressed, 15 recovered) and 23 age- and gender-matched non-smoking controls had one [123I]5-I-A-85380 SPECT scan and one MRI; β2*-nAChR availability was quantified as VT/fp.
- Postmortem study: [125I]5-I-A-85380 binding was analyzed in prefrontal cortex samples from 14 subjects with MDD and age-matched controls.
- Main analysis used linear mixed models with region as a within-subjects factor, diagnostic group as a between-subjects factor, and group-by-region interaction; post-hoc tests were Bonferroni-corrected for 11 regional comparisons (2-sided alpha=.0045). Clinical correlations, postmortem ANOVA, and voxel-based morphometry (SPM5, p<.05 uncorrected) were also performed.
Limitations
- The paper states the sample size is relatively small and composed nearly entirely of subjects without a past history of cigarette smoking; only 11 of 46 subjects had a past smoking history, so the relationship between past smoking and β2*-nAChR availability could not be adequately analyzed.
- The paper states SPECT limitations include absence of a quantifiable reference region and input function, absence of a measurement of non-displaceable binding in MDD patients, poor resolution for small regions such as the amygdala, and the need for a PET study to confirm results; use of current non-smokers limits generalizability.
- Evident from the text: the postmortem results are described as provided in the supplement, limiting detail in the main paper, and the cross-sectional design cannot establish whether cholinergic changes are a cause or effect of MDD.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Not checked yet · 10 Own method · 10 Own result · 7 Own interpretation
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was a significant overall group effect (F(1,21)=10.0, p=0.005) with lower overall β2*-nAChR availability observed among acute MDD patients compared to recovered patients.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Results for SPECT study
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Post hoc comparison revealed decreased β2*-nAChR availability in aMDD subjects compared to healthy controls in nine of the eleven ROIs examined (except hippocampus and amygdala, all adjusted p<0.007).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Results for SPECT study
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This was also observed in the rMDD group alone (temporal cortex r=0.54, p=0.036, occipital cortex r=0.56, p=0.03, thalamus r=0.54, p=0.038 and striatum r=0.58, p=0.022).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Correlation with clinical features
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CTQ total score and emotional abuse subscale were negatively correlated with receptor availability in all ROIs studied except amygdala in the aMDD but not the rMDD group.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Correlation with clinical features
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Post hoc comparisons showed lower β2*-nAChR availability among patients compared to controls in the frontal cortex (adjusted p=0.03), anterior cingulate (adjusted p=0.04), and thalamus (adjusted p=0.008).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Results for SPECT study
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When aMDD and rMDD groups were combined, there was a significant positive correlation between lifetime number of episodes and β2*-nAChR availability in temporal cortex (r=0.46, p=0.049), occipital cortex (r=0.48, p=0.037), and striatum (r=0.49, p=0.034).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Correlation with clinical features
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“NEO conscientiousness scores were significantly correlated with receptor availability in all ROIs studied except amygdala and brainstem (which showed a trend for significance) in the aMDD group but not the rMDD group.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Correlation with clinical features
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no differences in β2*-nAChR number between groups in the human postmortem study.”
- Also stated in: § Postmortem studies · plain
“the postmortem samples show no change in receptor number in patients with MDD when compared with either controls.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Postmortem brain samples are free of endogenous acetylcholine, so their β2*-nAChR binding reflects receptor number.
- Also stated in: § Postmortem studies · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“β2*-nAChR availability is decreased in patients with MDD.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > Abstract > Conclusion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“These results, together with the non-human primate study (27), suggest that when β2*-nAChR availability is measured in the absence of bound endogenous ACh, there is no evidence of a change in receptor number.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Postmortem studies
What the sources say
- Not checked yetcites [27] source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Postmortem brain samples are free of endogenous acetylcholine, so their β2*-nAChR binding reflects receptor number.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 15
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The STAI Trait subscale score was negatively correlated with receptor availability in anterior cingulate (r=−0.65, p=0.027), temporal (r=−0.64, p=0.026) and, occipital (r=−0.65, p=0.021) regions and showed a trend for significance in striatum (r=−0.51, p=0.09) in the rMDD group but not in the aMDD group.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Correlation with clinical features
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An SPM analysis of brain volumes of all MDD subjects compared to all controls showed no significant changes in volume in this population even at the relatively generous threshold used in the analysis. Similarly, there were no significant changes in volume between the aMDD subjects and their respective controls, the rMDD subjects and their respective controls, or between the aMDD and rMDD subjects.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Correlation with clinical features
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“nAChRs have a ubiquitous role in the modulation of multiple neurotransmitter systems considered crucial in the pathophysiology of MDD such as serotonin, noradrenaline, glutamate and GABA (43) and the observed dysfunction may reflect a cause or effect of dysfunction in these other systems.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Use of [123I]5-IA to quantify β2*-nAChR availability
What the sources say
- Not checked yetcites [43] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The continued, significant decrease in β2*-nAChR availability in fully recovered, euthymic, medication free rMDD subjects suggests that the changes in MDD are not an epiphenomenon of treatment or illness but may be associated with trait vulnerability to depression as demonstrated by us previously for other targets (26, 41, 42).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Use of [123I]5-IA to quantify β2*-nAChR availability
What the sources say
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Studies suggest that tobacco smokers have higher β2*-nAChR availability compared with non-smokers in non-psychiatric populations (34) which normalizes by 6–12 weeks of abstinence (44).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Functional consequences of lower β2*-nAChR availability
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, lower binding of [123I]5-IA to the β2*-nAChR could reflect one of two processes: an actual, absolute change in the amount of receptor or a change in synaptic ACh levels, such that an increased amount of ACh would prevent the radioligand from binding to the receptor, resulting in low binding of the radioligand.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 1. Introduction
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Notwithstanding the robust statistical significance of the SPECT binding results, the sample size of the population studied is relatively small and composed nearly entirely of subjects without a past history of cigarette smoking; only 11 of the 46 subjects studied had a past history of cigarette smoking.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Functional consequences of lower β2*-nAChR availability
plainn = 46- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“First, cholinergic hyperactivity plays a role in the pathophysiology of depression (2–4) and can exacerbate depression-like symptoms in patients and controls (4–6).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 1. Introduction
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Population-based studies show that smokers are twice as likely as nonsmokers to have a lifetime history of major depression (11–13).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 1. Introduction
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Clinical and demographic characteristics of participants in each group are shown in Table 2; the groups were well matched on most parameters studied though there were significant differences in ethnicity and lifetime smoking history between the groups.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Results for SPECT study
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All data were approximately normal.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 2. Materials and Methods > 2.4 Statistical analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Inclusion of age and gender as co-variates did not alter results and were therefore dropped from the analysis.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 2. Materials and Methods > 2.4 Statistical analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The use of a population exclusively composed of current non-smokers while essential to interpretation of the results limits generalizability and should be examined in future studies.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Functional consequences of lower β2*-nAChR availability
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study was approved by the Yale University School of Medicine Human Investigation Committee and the Radiation Safety Committee. After complete description of the study to the subjects, written informed consent was obtained. The use of the radiotracer [123I]5-IA was approved by the US Food and Drug Administration.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 2. Materials and Methods > 2. 1. Methods for SPECT Study
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“While the amygdala is a crucial structure in the pathophysiology of depression, SPECT has poor resolution for small brain regions and the findings for the amygdala should be interpreted with caution a.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Functional consequences of lower β2*-nAChR availability
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Second, tobacco dependence is highly prevalent in MDD populations (7) and MDD patients have a higher prevalence of smokers (8–10).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 1. Introduction
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant differences in the total injected dose, bolus dose, infusion dose, and bolus to infusion ratio between depressed and control groups (Table 1).”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 2. Materials and Methods > 2. 1. Methods for SPECT Study
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Inter-rater variability for VT/fp was <10% across all regions, which was computed as percent difference between two raters via following equation [(VT/fp 1/VT/fp 2)−1]*100=% difference.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 2. Materials and Methods > 2. 1. Methods for SPECT Study
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The relationship between a history of past cigarette smoking and β2*-nAChR availability could not be studied because of the small and unbalanced number of subjects with a past history of cigarette smoking.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Correlation with clinical features
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, nicotine binds to neuronal nicotinic acetylcholine receptors (nAChRs) and partial agonists and antagonists of nAChRs including nicotine (14), mecamylamine and dihydro-beta-erythroidine (DHβE) (15), cytisine (16) and varenicline (17), have antidepressant-like effects in preclinical studies.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 1. Introduction
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Analogous to findings from radioligand based studies of dopamine in humans, it is critically important to note that changes in receptor availability in vivo could be due to a change in receptor number or a change in receptor occupancy.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 1. Introduction
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The difference between β2*-nAChR availability in vivo and in postmortem samples may be analogous to data with dopaminergic PET ligands and dopamine receptor availability; lower receptor availability for the SPECT ligand could be caused by increased endogenous acetylcholine.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > Abstract > Conclusion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper relies on this without support.
Postmortem brain samples are free of endogenous acetylcholine, so their β2*-nAChR binding reflects receptor number.
“β2*-nAChR availability in the postmortem human samples, in the absence of endogenous acetylcholine, would help interpret the precise mechanism of potential changes in binding observed with [123I]5-IA in humans.”
“under conditions that washed out any endogenous bound ACh”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“supports the idea that the elevated ACh levels observed in human subjects who are actively depressed contributes to the disorder (Saricicek et al. 2012;Hannestad et al. 2013).”
From Mechanisms of Nicotine Addiction (2021) · cites this paper as Saricicek et al. 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Notably, anomalies in the availability or expression of specific nAChR subunits have been implicated in depression [104] and schizophrenia patients [105, 106].”
From Adolescent nicotine exposure and persistent neurocircuitry changes: unveiling lifelong psychiatric risks (2025) · cites this paper as [104]
In the citing paper
“More recently, human imaging and post mortem studies suggested that there is increased occupancy of nAChRs by ACh that is highest in individuals who are actively depressed and intermediate in those who have a history of depression with no change in overall nAChR number (Saricicek et al., 2012).”
From Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior (2012) · cites this paper as Saricicek et al., 2012
In the citing paper
“Recent imaging studies have shown that availability of β2* nAChRs for tracer binding was greatly decreased in actively depressed patients but was intermediate in remitted subjects (Saricicek et al., 2012).”
From Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states (2015) · cites this paper as Saricicek et al., 2012
Statistics that don’t add up
Each reported p-value recomputed from its test statistic and degrees of freedom.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“F(3,42)=8.65, p<.0001”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Results for SPECT study
Reported p < .0001 · recomputed p < .001
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Doesn’t add upF(3, 42) = 8.65reported p < .0001 · recomputed p < .001
“F(3,42)=8.65, p < .0001”
- ConsistentF(30, 420) = 1.82reported p = .006 · recomputed p = .006
“F(30,420)=1.82, p = .006”
- ConsistentF(1, 14) = 15.8reported p = .0014 · recomputed p = .001
“F(1,14)=15.8, p = .0014”
- ConsistentF(10, 140) = 2.52reported p = .008 · recomputed p = .008
“F(10,140)=2.52, p = .008”
- ConsistentF(1, 28) = 7.9reported p = .009 · recomputed p = .009
“F(1, 28)=7.9, p = .009”
- ConsistentF(1, 21) = 10reported p = .005 · recomputed p = .005
“F(1,21)=10.0, p = .005”
- ConsistentF(10, 210) = 1.34reported p = .21 · recomputed p = .211
“F(10,210)=1.34, p = .21”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > Abstract > Results
“β2*-nAChR availability in aMDD and rMDD subjects was significantly lower across all brain regions than in respective controls”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 3. Results > Results for SPECT study
“Post hoc comparison revealed decreased β2*-nAChR availability in aMDD subjects compared to healthy controls in nine of the eleven ROIs examined (except hippocampus and amygdala, all adjusted p<0.007).”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Functional consequences of lower β2*-nAChR availability
“Assuming that the lower β2*-nAChR availability represents increased extracellular ACh levels, the correlation implies that the greater the number of episodes, the greater the amount of extracellular ACh.”
§ Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder > 4. Discussion > Functional consequences of lower β2*-nAChR availability
“We observed a significant positive correlation between the number of depressive episodes and β2*-nAChR availability in the combined MDD sample and rMDD patients.”
Citations
Cites
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Ashburner, J., & Friston, K. J. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.02.018 · Cited by 7,507
The link between childhood trauma and depression: insights from HPA axis studies in humans
Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704
Bunney, W. E., Hippius, H., Laakmann, G., & Schmauß, M. (1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Grant, B. F., Hasin, D. S., Chou, S. P., Stinson, F. S., & Dawson, D. A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1107 · Cited by 1,262
A cholinergic-adrenergic hypothesis of mania and depression
Janowsky, D., Davis, J., El-Yousef, M. K., & Sekerke, H. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)93021-8 · Cited by 1,134
Prevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058
Bora, E., Fornito, A., Pantelis, C., & Yücel, M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.049 · Cited by 763
Cigarette smoking: implications for psychiatric illness
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.546 · Cited by 723
Research works printed but not linked: 5
- Fujita M, 2000, J Nucl Med, 41, 1552
- Staley JK, 2005, J Nucl Med, 46, 1466
- First MB, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders—Clinician Version (SCID-CV)
- Beck AT, 1996, Beck Depression Inventory, 2nd ed, Manual
- Costa PT, 1992, NEO PI-R Professional Manual
Cited by
Sorted by citations
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Self-citationMineur, Y. S., Obayemi, A., Wigestrand, M. B., Fote, G. M., Calarco, C. A., Li, A. M., & Picciotto, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219731110 · Cited by 375
Self-citationCholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
Dulawa, S. C., & Janowsky, D. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0219-x · Cited by 187
Neuromodulation by acetylcholine: examples from schizophrenia and depression
Higley, M. J., & Picciotto, M. R. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.06.004 · Cited by 184
Self-citationDavis, M. T., Holmes, S. E., Pietrzak, R. H., & Esterlis, I. (2017) · Chronic Stress · doi:10.1177/2470547017710916 · Cited by 194
Self-citationMechanisms of Nicotine Addiction
Picciotto, M. R., & Kenny, P. J. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039610 · Cited by 161
Self-citationPicciotto, M. R., Lewis, A. S., van Schalkwyk, G. I., & Mineur, Y. S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.028 · Cited by 157
Self-citationNeurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Faye, C., McGowan, J. C., Denny, C. A., & David, D. J. P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170818095105 · Cited by 143
Molecules and circuits involved in nicotine addiction: The many faces of smoking
Picciotto, M. R., & Mineur, Y. S. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.028 · Cited by 123
Self-citationThe catecholaminergic–cholinergic balance hypothesis of bipolar disorder revisited
van Enkhuizen, J., Janowsky, D. S., Olivier, B., Minassian, A., Perry, W., Young, J. W., & Geyer, M. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.05.063 · Cited by 111
Hillmer, A. T., Esterlis, I., Gallezot, J., Bois, F., Zheng, M.-Q., Nabulsi, N., Lin, S., Papke, R. L., Huang, Y. H., Sabri, O., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.07.026 · Cited by 100
Self-citationNicotinic acetylcholine receptors in neurological and psychiatric diseases
Terry, A. V., Jones, K., & Bertrand, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106764 · Cited by 90
Mineur, Y. S., Fote, G. M., Blakeman, S., Cahuzac, E. L. M., Newbold, S. A., & Picciotto, M. R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.316 · Cited by 90
Self-citationNicotinic receptors mediate stress-nicotine detrimental interplay via dopamine cells’ activity
Morel, C., Fernández, S. P., Pantouli, F., Meye, F. J., Marti, F., Tolu, S., Parnaudeau, S., Marie, H., Tronche, F., Maskos, U., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.145 · Cited by 88
The role of acetylcholine in negative encoding bias: Too much of a good thing?
Mineur, Y. S., & Picciotto, M. R. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14641 · Cited by 78
Self-citationContributions of animal models to the study of mood disorders
Valvassori, S. S., Budni, J., Varela, R. B., & Quevedo, J. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1168 · Cited by 78
Mineur, Y. S., Cahuzac, E. L. M., Mose, T. N., Bentham, M. P., Plantenga, M. E., Thompson, D. C., & Picciotto, M. R. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0024-x · Cited by 71
Self-citationMineur, Y. S., Mose, T. N., Blakeman, S., & Picciotto, M. R. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13769 · Cited by 71
Self-citationInvestigating the mechanism(s) underlying switching between states in bipolar disorder
Young, J. W., & Dulcis, D. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.019 · Cited by 68
Hannestad, J. O., Cosgrove, K. P., DellaGioia, N. F., Perkins, E., Bois, F., Bhagwagar, Z., Seibyl, J. P., McClure-Begley, T. D., Picciotto, M. R., & Esterlis, I. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.004 · Cited by 63
Self-citationDown-regulation of cholinergic signaling in the habenula induces anhedonia-like behavior
Han, S., Yang, S. H., Kim, J. Y., Mo, S., Yang, E., Song, K. M., Ham, B., Mechawar, N., Turecki, G., Lee, H. W., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01088-6 · Cited by 67
Mixed States in Bipolar Disorder: Etiology, Pathogenesis and Treatment
Muneer, A. (2017) · Chonnam Medical Journal · doi:10.4068/cmj.2017.53.1.1 · Cited by 62
Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression
Gandelman, J. A., NEWHOUSE, P. A., & Taylor, W. D. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.018 · Cited by 61
Sabri, O., Becker, G., Meyer, P., Hesse, S., Wilke, S., Graef, S., Patt, M., Luthardt, J., Wagenknecht, G., Hoepping, A., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.05.065 · Cited by 59
Recent Developments in Novel Antidepressants Targeting α4β2-Nicotinic Acetylcholine Receptors
Yu, L.-F., Zhang, H.-K., Caldarone, B. J., Eaton, J. B., Lukas, R. J., & Kozikowski, A. P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401937a · Cited by 56
Esterlis, I., Ranganathan, M., Bois, F., Pittman, B. P., Picciotto, M. R., Shearer, L., Anticevic, A., Carlson, J., Niciu, M. J., Cosgrove, K., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.001 · Cited by 53
Self-citationMineur, Y. S., Mose, T. N., Vanopdenbosch, L., Etherington, I. M., Ogbejesi, C., Islam, A., Pineda, C. M., Crouse, R. B., Zhou, W., Thompson, D. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01404-7 · Cited by 48
Self-citationNicotine and alcohol: the role of midbrain dopaminergic neurons in drug reinforcement
Morel, C., Montgomery, S. E., & Han, M. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14160 · Cited by 50
van Enkhuizen, J., Milienne-Petiot, M., Geyer, M. A., & Young, J. W. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4000-4 · Cited by 46
Güleş, E., Iosifescu, D. V., & Tural, Ü. (2020) · Neuropsychobiology · doi:10.1159/000505782 · Cited by 42
Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test
Addy, N. A., Nunes, E. J., & Wickham, R. J. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.04.002 · Cited by 42
Pathophysiology of nAChRs: Limbic circuits and related disorders
Mineur, Y. S., Soares, A. R., Etherington, I. M., Abdulla, Z. I., & Picciotto, M. R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106745 · Cited by 42
Self-citationImaging changes in synaptic acetylcholine availability in living human subjects
Esterlis, I., Hannestad, J. O., Bois, F., Sewell, R. A., Tyndale, R. F., Seibyl, J. P., Picciotto, M. R., Laruelle, M., Carson, R. E., & Cosgrove, K. P. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111922 · Cited by 38
Self-citationLewis, A. S., & Picciotto, M. R. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3126-5 · Cited by 38
Self-citationMineur, Y. S., & Picciotto, M. R. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15943 · Cited by 38
Self-citationImaging Habenula Volume in Schizophrenia and Bipolar Disorder
Schafer, M., Kim, J.-W., Joseph, J., Xu, J., Frangou, S., & Doucet, G. E. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00456 · Cited by 36
Mineur, Y. S., Einstein, E. B., Bentham, M. P., Wigestrand, M. B., Blakeman, S., Newbold, S. A., & Picciotto, M. R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.269 · Cited by 34
Self-citationMajor depression and electrovestibulography
Lithgow, B., Garrett, A., Moussavi, Z. M. K., Gurvich, C., Kulkarni, J., Maller, J. J., & Fitzgerald, P. B. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1014410 · Cited by 32
Mineur, Y. S., Bentham, M. P., Zhou, W., Plantenga, M. E., McKee, S. A., & Picciotto, M. R. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4001-3 · Cited by 31
Self-citationArias, H. R., Targowska‐Duda, K. M., García‐Colunga, J., & Ortells, M. O. (2021) · Molecules · doi:10.3390/molecules26082149 · Cited by 30
Reynolds, L. M., Faure, P., & Barik, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03110-0 · Cited by 26
Fischer, S., Hiller, A., Smits, R., Hoepping, A., Funke, U., Wenzel, B., Cumming, P. D., Sabri, O., Steinbach, J., & Brust, P. (2013) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2013.01.002 · Cited by 22
Mohammadi, S. A., Burton, T. J., & Christie, M. J. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.04.005 · Cited by 23
Neves, G. A., & Grace, A. A. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.009 · Cited by 22
The role of estrogen receptor β and nicotinic cholinergic receptors in postpartum depression
Fernandez, J. W., Grizzell, J. A., & Wecker, L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.002 · Cited by 20
Cognition as a therapeutic target in late-life depression: Potential for nicotinic therapeutics
Zurkovsky, L., Taylor, W. D., & NEWHOUSE, P. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.032 · Cited by 20
Cytisine: State of the art in pharmacological activities and pharmacokinetics
Wang, X., Yang, J., Huang, P., Wang, D., Zhang, Z., Zhou, Z., Liang, L., Yao, R., & Long, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116210 · Cited by 22
Bois, F., Gallezot, J., Zheng, M., Lin, S.-F., Esterlis, I., Cosgrove, K., Carson, R. E., & Huang, Y. H. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.08.003 · Cited by 19
Self-citationWeber, M. L., Hofland, C. M., Shaffer, C. L., Flik, G., Cremers, T. I. F. H., Hurst, R. S., & Rollema, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.027 · Cited by 19
Lithgow, B., Moussavi, Z., & Fitzgerald, P. B. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1599143 · Cited by 19
Hillmer, A., Wooten, D. W., Slesarev, M. S., Ahlers, E. O., Barnhart, T., Schneider, M., Mukherjee, J., & Christian, B. (2013) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1038/jcbfm.2013.136 · Cited by 16
Kan, H., Peng, W., Wu, C., Wang, D., Lee, M. T., Lee, Y., Chu, T., & Ho, Y. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06250-1 · Cited by 19
Yu, N., Song, H., Chu, G., Zhan, X., Liu, B., Mu, Y., Wang, J., & Lu, Y. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00962-2 · Cited by 20
Roberts, W., Verplaetse, T. L., Moore, K. E., Oberleitner, L., Picciotto, M. R., & McKee, S. A. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699618 · Cited by 18
Self-citationPádua-Reis, M., Aquino, N. S. S., Oliveira, V. E. D. M., Szawka, R. E., Prado, M. A. M., Prado, V. F., & Pereira, G. S. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.04.049 · Cited by 17
McClure‐Begley, T. D., Esterlis, I., Stone, K. L., Lam, T. T., Grady, S. R., Colangelo, C. M., Lindstrom, J. M., Marks, M. J., & Picciotto, M. R. (2016) · eNeuro · doi:10.1523/eneuro.0166-16.2016 · Cited by 16
Self-citationMcCloskey, M. C., Young, T. J., & Anderson, S. M. (2017) · BIOS · doi:10.1893/bios-d-15-00013.1 · Cited by 16
Cope, Z. A., Lavadia, M. L., Joosen, A., van de Cappelle, C. J. A., Lara, J. C., Huval, A., Kwiatkowski, M. K., Picciotto, M. R., Mineur, Y. S., Dulcis, D., et al. (2020) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-020-00824-2 · Cited by 15
Self-citationProtective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models
Yu, Z., Kong, D., Liang, Y., Zhao, X., & Du, G. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.002 · Cited by 15
Antidepressant-like effect of active fraction of Polyrhachisvicina Roger in a rat depression model
Guining, W., Shifeng, C., Su, Q., Hua, S., Meiyu, L., He, F., Lu, W.-J., Guoshou, L., Zhoufeng, H., Xiao, T., et al. (2018) · 中医杂志：英文版 · doi:10.1016/j.jtcm.2018.02.001 · Cited by 15
Zhang, E., Hauson, A. O., Pollard, A. A., Meis, B., Lackey, N. S., Carson, B., Khayat, S., Fortea, L., & Raduà, J. (2023) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2023.111691 · Cited by 14
Khadrawy, Y. A., Sawie, H. G., Hosny, E. N., & Mourad, H. H. (2018) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-018-0034-1 · Cited by 13
Sun, X., Sun, C., Zhai, L., & Dong, W. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02891-5 · Cited by 13
Dietary Capsaicin Exacerbates Gut Microbiota Dysbiosis and Mental Disorders in Type 1 Diabetes Mice
Zhang, X., Hu, H., Zhang, Y., Hu, S., Ji, L., Peng, W., & Luo, D. (2025) · Nutrients · doi:10.3390/nu17030593 · Cited by 12
Madsen, H. B., Koghar, H. S., Pooters, T., Massalas, J. S., Drago, J., & Lawrence, A. J. (2014) · Addiction Biology · doi:10.1111/adb.12148 · Cited by 15
Roles of N-Acylethanolamines in Brain Functions and Neuropsychiatric Diseases
Pistis, M., & Muntoni, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-57371-7_11 · Cited by 12
Evaluation of (‐)‐[18 F]F lubatine‐specific binding: Implications for reference region approaches
Bhatt, S., Hillmer, A. T., Nabulsi, N., Matuskey, D., Lim, K., Lin, S.-F., Esterlis, I., Carson, R. E., Huang, Y. H., & Cosgrove, K. (2017) · Synapse · doi:10.1002/syn.22016 · Cited by 12
Self-citationDesigning selective modulators for the nicotinic receptor subtypes: challenges and opportunities.
Manetti, D., Bellucci, C., Chiaramonte, N., Dei, S., Teodori, E., & Romanelli, M. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0169 · Cited by 15
Abdulla, Z. I., Mineur, Y. S., Crouse, R. B., Etherington, I. M., Yousuf, H., Na, J. J., & Picciotto, M. R. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-02003-0 · Cited by 11
Self-citationNgadni, M. A., Akhtar, M. T., Ismail, I. S., Norazhar, A. I., Lee, S. Y., Maulidiani, M., & Shaari, K. (2021) · Molecules · doi:10.3390/molecules26144137 · Cited by 11
LPS-induced impairment of Na+/K+-ATPase activity: ameliorative effect of tannic acid in mice
Luduvico, K. P., Spohr, L., Soares, M. S. P., Teixeira, F. C., Bona, N. P., de Mello, J. E., Spanevello, R. M., & Stefanello, F. M. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01036-y · Cited by 11
Bassi, S., Seney, M. L., Argibay, P. F., & Sibille, E. L. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.02.006 · Cited by 13
Mantanona, C. P., Alsiö, J., Elson, J. L., Fisher, B. M., Dalley, J. W., Bussey, T. J., & Pienaar, I. S. (2019) · Brain Structure and Function · doi:10.1007/s00429-019-01957-y · Cited by 13
Storage, S. S., Mandelkern, M. A., Phuong, J., Kozman, M., Neary, M. K., & Brody, A. L. (2013) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2013.07.010 · Cited by 10
Fogaça, M. V., Fedoce, A. G., Ferreira‐Junior, N. C., Guimarães, F. S., & Resstel, L. B. M. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4228-7 · Cited by 10
Bambico, F. R., Li, Z., Creed, M. C., Gregorio, D. D., Diwan, M., Li, J. L., McNeill, S., Gobbi, G., Raymond, R., & Nóbrega, J. N. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz187 · Cited by 12
Dean, B., Pavey, G., & Scarr, E. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.034 · Cited by 9
Proud, E., Rodríguez-Ruiz, M., Gummerson, D., Vanin, S., Hardy, D. B., Rushlow, W. J., & Laviolette, S. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1473213 · Cited by 9
PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain
Smart, K. A., Naganawa, M., Baldassarri, S. R., Nabulsi, N., Ropchan, J. R., Najafzadeh, S., Gao, H., Navarro, A., Barth, V., Esterlis, I., et al. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa387 · Cited by 8
Self-citationAnticholinergics: A potential option for preventing posttraumatic epilepsy
Sanabria, V., Romariz, S. A. A., Braga, M., Foresti, M. L., Naffah‐Mazzacoratti, M. D. G., Mello, L. E., & Longo, B. M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1100256 · Cited by 7
Akinduko, A., Salawu, S. O., Akinmoladun, A. C., Akindahunsi, A. A., & Osemwegie, O. O. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117597 · Cited by 10
Ishola, I. O., Olubodun-Obadun, T. G., Bakre, O. A., Ojo, E. S., & Adeyemi, O. O. (2022) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2021-0125 · Cited by 9
Nirogi, R. V. S., Abraham, R., Jayarajan, P., Goura, V., Kallepalli, R., Medapati, R. B., Tadiparthi, J., Goyal, V., Pandey, S. K., Subramanian, R., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06108-6 · Cited by 8
Li, S., Yu, B., Wang, D., Xia, L., Wang, L., Chen, D., Xiu, M., & Zhang, X. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.143 · Cited by 7
Targowska‐Duda, K. M., Arias, H. R., & Jóźwiak, K. (2013) · The Open Conference Proceedings Journal · Cited by 7
Nicotinic acetylcholine receptors-targeting drug discovery
Zhang, D., Zheng, H., Cui, K., Li, Y., Liu, C., Mao, J., Zheng, J., & Wan, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118679 · Cited by 6
Valli, M., Betti, A. H., Danuello, A., Pivatto, M., Centurião, F. B., Antonio, C. B., Rates, S. M. K., & Bolzani, V. D. S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.02.050 · Cited by 5
Preclinical and Clinical Aspects of Nicotinic Acetylcholine Receptor Imaging
Brust, P., Deuther‐Conrad, W., Donat, C. K., Barthel, H., Riss, P. J., Paterson, L. M., Hoepping, A., Sabri, O., & Cumming, P. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_18 · Cited by 5
Acetylcholine and Depression: Scrutinizing Future Therapeutic Targets for Novel Drug Development
Pannu, A. S., & Goyal, R. K. (2024) · Current Clinical Pharmacology · doi:10.2174/0127724328311930240907133618 · Cited by 5
Quintanilha, T. M., Costa, P. M., Cardoso, A. L. S., Battú, G. D. S., Bastos, L. M., dos Santos, B. P., Müller, T. E., de Oliveira, T. F., Piato, Â., Kalueff, A. V., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70116 · Cited by 4
Preclinical Aspects of Nicotinic Acetylcholine Receptor Imaging
Brust, P., Deuther‐Conrad, W., Donat, C. K., Barthel, H., Riss, P. J., Paterson, L. M., Hoepping, A., Sabri, O., & Cumming, P. D. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_17 · Cited by 4
Gibbons, A., McPherson, K., Gogos, A., & Dean, B. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.007 · Cited by 4
(2016) · Neurotransmitter · doi:10.14800/nt.1293 · Cited by 4
Park, D., Lee, G., Kim, B. S., Seong, M., & Kim, J. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02288-9 · Cited by 3
Szerman, N., Carlos, P., Pinet, C., Martínez-Raga, J., Basurte, I., & Sáiz, P. A. (2022) · Actas Españolas de Psiquiatría · Cited by 4
Kim, J., Kleinfelter, B., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01908-0 · Cited by 3
Trajectories of late-life depression: insights from molecular imaging
Holmes, S. E., & Smith, G. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02340-2 · Cited by 2
Cholinergic Protection in Ischemic Brain Injury
Uteshev, V. V. (2017) · Springer series in translational stroke research · doi:10.1007/978-3-319-45345-3_17 · Cited by 2
Bao, K. H. (2021) · Research Square · doi:10.21203/rs.3.rs-374465/v1 · Cited by 2
Nicotinic Receptors and Mental Illness
Leonard, S. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1167-7_20 · Cited by 1
Metadata
- Authors
- Saricicek, A., Esterlis, I., Maloney, K. H., Mineur, Y. S., Ruf, B. M., Muralidharan, A., Chen, J. I., Cosgrove, K. P., Kerestes, R., Ghose, S., Tamminga, C. A., Pittman, B., Bois, F., Tamagnan, G., Seibyl, J., Picciotto, M. R., Staley, J. K., & Bhagwagar, Z.
- Affiliations
- From the Department of Psychiatry, Yale University, New Haven, Conn.; the Neuroscience Group, Bristol-Myers Squibb, Wallingford, Conn.; the Institute for Neurodegenerative Disorders, New Haven, Conn.; and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas.
- Yale University (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2012-08
- Volume
- 169
- Issue
- 8
- Pages
- 851-859
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC3494404
- OpenAlex
- W2012803743
- Semantic Scholar
- 509ecb3712492199234e49435e4fb63c5347c8ae
- Cited by
- 118
- References
- 49
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 5 · 2023: 8 · 2022: 8 · 2021: 5 · 2020: 6 · 2019: 9 · 2018: 9 · 2017: 14 · 2016: 5 · 2015: 10 · 2014: 11 · 2013: 12 · 2012: 5
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5k23mh077914-02)
- National Institute of Mental Health (MH077681, K23-MH077914, P50MH096890, MH-077914, R01MH077681)
- National Center for Research Resources (UL1RR024139)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- major depressive disorder, nicotinic acetylcholine receptors, beta2 subunit, receptor availability, prefrontal cortex, postmortem brain, endogenous acetylcholine, trauma, anxiety, depressive episodes, recovered depression
- MeSH terms
- Adult, Brain, Major Depressive Disorder, Depressive Disorder, Major, Female, Humans, Magnetic Resonance Imaging, Male, Psychiatric Status Rating Scales, Receptors, Nicotinic, Tomography, Emission-Computed, Single-Photon, Case-Control Studies, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
